On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs)

Santini, V., Fenaux, P., Van Eygen, K., Raza, A., Germing, U., Font, P., Diez-Campelo, M., Thepot, S., Vellenga, E., Patnaik, M. M., Jang, J. H., Sherman, L., Berry, T., Feller, F., Dougherty, S., Sun, L., Wan, Y., Rizo, A., Huang, F., & Platzbecker, U. (2021). On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs). Blood, 138(Supplement 1), 2598–2598. https://doi.org/10.1182/blood-2021-148876

Authors:

Valeria Santini

Pierre Fenaux

Koen Van Eygen

Azra Raza

Ulrich Germing

Patricia Font

María Diez‐Campelo

Sylvain Thépot

Edo Vellenga

Mrinal M. Patnaik

Jun Ho Jang